Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Neven

Showing results (241-250 of 383) with videos related to

Pageof 39
Sort By:
Clinical Chemistry|November 3, 2020
Breast Cancer Detection and Treatment Monitoring Using a Noninvasive Prenatal Testing Platform: Utility in Pregnant and Nonpregnant PopulationsLiesbeth Lenaerts, Huiwen Che, Nathalie Brison, et al.
Journal of the National Cancer Institute|November 5, 2020
Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast CancerGiuseppe Floris, François Richard, Anne-Sophie Hamy, et al.
Breast (Edinburgh, Scotland)|October 16, 2020
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 studyPeter A Fasching, J Thaddeus Beck, Arlene Chan, et al.
Menopause (New York, N.Y.)|October 1, 2010
Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozoleBen Van Calster, Johan Van Ginderachter, Jos Vlasselaer, et al.
Breast Cancer Research and Treatment|September 14, 2007
A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapyStephen R D Johnston, Vladimir F Semiglazov, George M Manikhas, et al.
Breast Cancer Research : BCR|June 12, 2023
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral diseasePeter Schmid, Javier Cortes, Ana Joaquim, et al.
The Journal of Pathology|September 30, 2024
Dissecting the immune infiltrate of primary luminal B-like breast carcinomas in relation to ageSigrid Hatse, Yentl Lambrechts, Asier Antoranz Martinez, et al.
Breast Cancer Research and Treatment|February 12, 2020
Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activityCharlotte Rypens, Melike Marsan, Christophe Van Berckelaer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2008
In early-stage breast cancer, the estrogen receptor interacts with correlation between human epidermal growth factor receptor 2 status and age at diagnosis, tumor grade, and lymph node involvementPatrick Neven, Olivier Brouckaert, Vanya Van Belle, et al.
Breast Cancer Research and Treatment|November 7, 2020
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trialManuela Rabaglio, Zhuoxin Sun, Rudolf Maibach, et al.
Pageof 39

Showing results (241-250 of 383) with videos related to

Sort By:
Pageof 39
Clinical Chemistry|November 3, 2020
Breast Cancer Detection and Treatment Monitoring Using a Noninvasive Prenatal Testing Platform: Utility in Pregnant and Nonpregnant PopulationsLiesbeth Lenaerts, Huiwen Che, Nathalie Brison, et al.
Journal of the National Cancer Institute|November 5, 2020
Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast CancerGiuseppe Floris, François Richard, Anne-Sophie Hamy, et al.
Breast (Edinburgh, Scotland)|October 16, 2020
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 studyPeter A Fasching, J Thaddeus Beck, Arlene Chan, et al.
Menopause (New York, N.Y.)|October 1, 2010
Uterine and quality of life changes in postmenopausal women with an asymptomatic tamoxifen-thickened endometrium randomized to continuation of tamoxifen or switching to anastrozoleBen Van Calster, Johan Van Ginderachter, Jos Vlasselaer, et al.
Breast Cancer Research and Treatment|September 14, 2007
A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapyStephen R D Johnston, Vladimir F Semiglazov, George M Manikhas, et al.
Breast Cancer Research : BCR|June 12, 2023
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral diseasePeter Schmid, Javier Cortes, Ana Joaquim, et al.
The Journal of Pathology|September 30, 2024
Dissecting the immune infiltrate of primary luminal B-like breast carcinomas in relation to ageSigrid Hatse, Yentl Lambrechts, Asier Antoranz Martinez, et al.
Breast Cancer Research and Treatment|February 12, 2020
Inflammatory breast cancer cells are characterized by abrogated TGFβ1-dependent cell motility and SMAD3 activityCharlotte Rypens, Melike Marsan, Christophe Van Berckelaer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2008
In early-stage breast cancer, the estrogen receptor interacts with correlation between human epidermal growth factor receptor 2 status and age at diagnosis, tumor grade, and lymph node involvementPatrick Neven, Olivier Brouckaert, Vanya Van Belle, et al.
Breast Cancer Research and Treatment|November 7, 2020
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trialManuela Rabaglio, Zhuoxin Sun, Rudolf Maibach, et al.
Pageof 39